Compare Davita Inc (DVA) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Raytheon Technologies Corp — how do they compare? Davita Inc trades at $232 (market cap $15.12B), while Raytheon Technologies Corp trades at $194.7 (market cap $264.48B). The key difference: Raytheon Technologies Corp is far larger — about 17.5× Davita Inc's market cap, and Raytheon Technologies Corp pays a 1.49% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | RTX | |
|---|---|---|
Market Cap | $15.12B | $264.48B |
Sector | Health | Industrials |
52-Week High | $235.71 | $212.16 |
52-Week Low | $103.87 | $148.68 |
Enterprise Value | $27.67B | $296.59B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RTX trades at $193.39, down 1.3% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.78 exceeding expectations of $1.51. Revenue grew to $88.60 billion in 2025, and net income margin improved to 8.03%. Recent contract wins, including a $515 million U.S. Navy radar award announced June 3, 2026, underscore its defense sector strength.
Outlook remains positive given earnings momentum and defense budget tailwinds, but valuation at a P/E of 36.85 poses a risk if growth slows. Analyst consensus price target of $213.00 suggests 10% upside, with no sell ratings among 26 coverage firms. Key risks include execution on production targets and geopolitical shifts affecting defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
